TriangleFOR PATIENTS · SOURCE READING
Treatment of Refractory or Recurrent Acute Myeloid Leukemia
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
There is no standard treatment for refractory or recurrent acute myeloid leukemia (AML). Treatment depends on the subtype of AML and may include:
Source links and citations
combination chemotherapy
Source links and citations
targeted therapy with enasidenib, gemtuzumab ozogamicin, gilteritinib, ivosidenib, or revumenib
Source links and citations
stem cell transplant using donor stem cells
Source links and citations
Learn more about these treatments in the Treatment Option Overview.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice